GlassScriptPhysician profile
Lan T Quach
NPI 1730462904
$16,297.42
in general payments reported to CMS, 2019-2025
20 companies · $4,303 in 2025
The $4,303 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,492 · 2022: $2,396 · 2023: $4,599 · 2024: $3,509 · 2025: $4,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $115 · Education: $60.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,234.08 |
| Consulting Fee | $115.00 |
| Education | $60.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,395.67 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,002.65 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,827.52 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,821.60 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,751.19 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,450.66 | 2021-2025 | Rexulti |
| Alkermes, INC. | $1,189.90 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,113.16 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $834.50 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $514.24 | 2022-2024 | Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $390.89 | 2022-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $286.59 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Brainsway USA INC | $162.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $130.70 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $128.25 | 2023 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.30 | 2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $115.00 | 2025 | Spravato |
| Avanir Pharmaceuticals, INC. | $24.53 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.20 | 2024 | Subvenite |
| Alfasigma USA, INC. | $16.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lan Quach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.